An Experimental Treatment could be Hope against Ovarian Cancer


The procedure could reduce the chances of relapse by up to 40%

There are doctors like oncologist Antonio Gonzalez Martín who dedicate a large part of his life to research. Specifically, he has been researching cancer for 25 years at the Ramon y Cajal University Hospital in Madrid. After so many years of struggle, he has managed to get an experimental treatment that could be the hope against ovarian cancer.

Hope against ovarian cancer is closer

Unfortunately, today most ovarian tumors are already diagnosed when they are in an advanced stage, which reduces the chances of patient survival. In fact, it is estimated that only 30% live up to 5 years with this type of tumor.

But after many studies, there may be hope against ovarian cancer. When evaluating 733 patients with this tumor, who went through chemotherapy treatment and then took the niraparib pill for 36 months, it was found that “ the risk of relapse is reduced by approximately 40%, ” says Dr. Gonzales in El País .

It should be noted that this drug boycotts cancer cells to restore damaged DNA.

The results of the research were presented at the congress of the European Society of Medical Oncology that took place days ago in Barcelona. Certainly, the data is very encouraging because a woman with a probability of a relapse of 80% can see that percentage reduced after taking niraparib. It should be noted that the study was disclosed in The New England Journal of Medicine .

Know here the symptoms of ovarian cancer.

The niraparib

The drug that may be the hope against ovarian cancer is included in the group of PARP inhibitors. This refers to a protein that restores the damaged parts in the DNA of the cells. Since the drug has the power to block PARP, it makes it impossible for cancer cells to remedy their mistakes. They can also work as a lever that turns off the malignant cells.

A remarkable fact is that niraparib has a better effect on females who have inherited malignant mutations in the BRCA1 gene  or in  BRCA2. These are more linked to ovarian or breast cancer.

Although the data is encouraging, caution must still be maintained and further investigation. However, if the drug continues to demonstrate effectiveness, it could save many lives, in addition to being a breakthrough in science.

Share This:


Please enter your comment!
Please enter your name here